Timed with the release of Star Wars: Episode III Revenge of the Sith, the original Battlefront II is far and away the best ...

The Rebel Hangar. The Snowspeeders in here are your only hope against the AT-AT. Use the tow cables to trip up their legs and you might just get off of Hoth alive! This Command Post can swing the ...

The massive walkers have such a large amount of shielding that often it is better to just ignore them and let your NPC comrades handle the destruction. If you really want to get involved, Cluster ...

NEW YORK, Sept. 4, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical innovator, today announced that it is leveraging Lantern Pharma's breakthrough ...

NEW YORK - Hoth Therapeutics, Inc. (NASDAQ:HOTH) announced Thursday it has begun using Lantern Pharma’s PredictBBB.ai platform, an artificial intelligence tool that predicts blood-brain barrier ...

NEW YORK, Sept. 2, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical innovator, today announced combined positive findings from multiple preclinical ...

(RTTNews) - Hoth Therapeutics, Inc. (HOTH) announced combined positive findings from multiple preclinical programs evaluating its precision antisense candidate HT-KIT, including compelling anti-tumor ...

HT-KIT reduced tumor size by day 8 and showed no organ toxicity in preclinical studies. The candidate remained stable in serum for 37 days at -80°C, exceeding benchmarks. Want to trade this news? Get ...

Investing.com -- Hoth Therapeutics Inc (NASDAQ:HOTH) stock surged 12.5% after the clinical-stage biopharmaceutical company announced positive preclinical results for its precision antisense candidate ...

Hoth Therapeutics Inc. (NASDAQ:HOTH) on Tuesday announced combined findings from multiple preclinical programs evaluating its precision antisense candidate HT-KIT. HT-KIT is a precision antisense ...

NEW YORK, Sept. 10, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical innovator, today announced it has submitted its Clinical Trial Application (CTA) to ...